Venetoclax may have a role as triple therapy with endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer because of its ability to kill senescent cancer cells, Victorian research suggests. A research team from the Walter and Eliza Hall Institute of Medical Research (WEHI) say relapse is almost inevitable for patients with ER+ breast cancer ...
Venetoclax triple therapy starts trials in ER+ breast cancer
By Michael Woodhead
13 May 2020